Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GE Institutional US Large Cap Core Equity Fund Investment Class (GEIVX)

Net Asset Value
1 Day
Overall Morningstar Rating
Large blend
Style or Category
No Load
Sales Expenses
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital and future income. The fund seeks to achieve its investment objectives by investing at least 80% of its net assets under normal circumstances in equity securities of large-capitalization U.S. companies, such as common and preferred stocks. It invests in U.S. large-cap companies (meaning companies with market capitalizations of $8 billion or more) that the portfolio managers believe are undervalued by the market but have solid growth prospects. The fund also may invest to a lesser extent in securities of foreign (non-U.S.) issuers and debt securities.


1 month0.00% 3 years+14.96%
3 months+9.14% 5 years+12.24%
1 year-1.62% Since inception+5.68%
Data through --

Peer Comparisonvs. Large blend

Performance 5-yr return+12.24%+11.68%
Expense ratio0.43%1.08%
Risk 5 year sharpe ratio0.971.01
Net assets$68.1M$3.6B
Average market cap$67.5B$101.5B
Average P/E17.019.3
Portfolio turnover45%45%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyGE Asset Management
Fund manager & tenureStephen Gelhaus / 13 Years
Minimal initial investment$5,000,000.00
Minimum IRA investment$0.00


U.S. stock93.73%
International stock3.84%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Financial service 20.87%
Energy 13.82%
Healthcare 12.06%
Industrial materials 9.40%
Consumer goods 9.14%
Top 10 Holdings
Portfolio weighting
GOOGL Google3.18%
AAPL Apple3.07%
JPM JPMorgan Chase2.98%
CSCO Cisco2.58%
PEP Pepsi2.48%
XOM Exxon Mobil2.41%
JNJ Johnson & Johnson2.40%
CMCSA Comcast2.33%
AGN Allergan2.16%
MRK Merck2.15%